Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia-Reference-Cited by-同舟云学术

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

Published:2021-02-01 Issue:8 Volume:35 Page:2358-2370
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Paiva Bruno^ORCID,Vidriales María-Belen^ORCID,Sempere Amparo,Tarín Fabián,Colado Enrique,Benavente Celina,Cedena María-Teresa,Sánchez Joaquín,Caballero-Velazquez Teresa,Cordón Lourdes^ORCID,Garces Juan-Jose^ORCID,Simoes Catia,Martínez-Cuadrón David^ORCID,Bernal Teresa^ORCID,Botella Carmen,Grille Sofia,Serrano Josefina,Rodríguez-Medina Carlos,Algarra Lorenzo,Alonso-Domínguez Juan-Manuel^ORCID,Amigo María-Luz^ORCID,Barrios Manuel,García-Boyero Raimundo,Colorado Mercedes,Pérez-Oteyza Jaime,Pérez-Encinas Manuel^ORCID,Costilla-Barriga Lisette,Sayas María-José,Pérez Olga,González-Díaz Marcos,Pérez-Simón José A.,Martínez-López Joaquín^ORCID,Sossa Claudia,Orfao Alberto^ORCID,San Miguel Jesús F.,Sanz Miguel-Ángel^ORCID,Montesinos Pau^ORCID,

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-021-01126-3.pdf

Reference49 articles.

1. Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–91.

2. Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62–70.

3. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

4. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–21.

5. Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34:329–36.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?;Blood Reviews;2024-08

2. Measurable residual disease in haematological and solid cancers;Leukemia;2024-06-27

3. Measurable residual disease (MRD)-testing in haematological and solid cancers;Leukemia;2024-04-18

4. Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions;Biomedicines;2024-03-07

5. Genetic mutation signature for relapse prediction in normal karyotype acute myeloid leukemia;Experimental Hematology;2023-12